Evidence map›Paper›PMID 42221586›Full record

ArticleFrontiers in cellular and infection microbiology2026

Pyrazinamide susceptibility testing in

Touyana Semenova, Grégory Gonzalez, Benoît Lechartier, Peter Sander, Christophe von Garnier, Bettina Schulthess, Jesica Mazza-Stalder, Gilbert Greub, Onya Opota

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Touyana SemenovaInstitute of Microbiology, Lausanne University and Lausanne University Hospital, Lausanne, Switzerland.
Grégory GonzalezInstitute of Microbiology, Lausanne University and Lausanne University Hospital, Lausanne, Switzerland.
Benoît LechartierDivision of Pulmonology, Department of Medicine, Lausanne University and Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Peter SanderInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
Christophe von GarnierDivision of Pulmonology, Department of Medicine, Lausanne University and Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Bettina SchulthessInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
Jesica Mazza-StalderDivision of Pulmonology, Department of Medicine, Lausanne University and Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Gilbert GreubInstitute of Microbiology, Lausanne University and Lausanne University Hospital, Lausanne, Switzerland.
Onya OpotaInstitute of Microbiology, Lausanne University and Lausanne University Hospital, Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The reliability of phenotypic pyrazinamide (PZA) drug susceptibility test (DST) in Results: Between 2023 and 2025, 9% of the isolates were confirmed as TP PZA-R, mostly due to Conclusions: Our data reveal a high FP rate for PZA-R with the MGIT 960 System, with no reliable phenotypic alternative available. The sequencing of

Indexed as

Antitubercular AgentsMycobacterium tuberculosisPyrazinamideTuberculosis, Multidrug-ResistantAmidohydrolasesDrug Resistance, Multiple, BacterialFalse Positive ReactionsHumansIncidenceMicrobial Sensitivity TestsAmidohydrolasesAntitubercular AgentsPyrazinamideAntibiotic resistanceantibiotic susceptibility testingMDR-TBmolecular diagnosisMycobacterium bovisMycobacterium tuberculosis complexpyrazinamideSanger and next-generation sequencing

Identifiers

PMID42221586
PMCPMC13216198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.